Daniel Hendler

4.7k total citations · 1 hit paper
19 papers, 3.2k citations indexed

About

Daniel Hendler is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniel Hendler has authored 19 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 6 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel Hendler's work include Cancer Treatment and Pharmacology (5 papers), Breast Cancer Treatment Studies (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Daniel Hendler is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Breast Cancer Treatment Studies (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Daniel Hendler collaborates with scholars based in Israel, France and Italy. Daniel Hendler's co-authors include Aimery de Gramont, Jim Cassidy, Filippo de Braud, F. Morvan, Christophe Louvet, Arié Figer, H. Cortés-Funes, Abdel Hmissi, N Le Bail and C. Wilson and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Daniel Hendler

17 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

2000 3.0k citations Aimery de Gramont, Arié Figer et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Hendler Israel	7	2.7k	899	824	685	407	19	3.2k
M. Homerin France	10	2.9k 1.1×	944 1.1×	883 1.1×	884 1.3×	423 1.0×	17	3.5k
C. Wilson Canada	6	2.7k 1.0×	899 1.0×	822 1.0×	729 1.1×	419 1.0×	9	3.2k
D. Papamichael United Kingdom	15	3.0k 1.1×	916 1.0×	958 1.2×	817 1.2×	567 1.4×	26	3.7k
Élisabeth Carola France	17	2.2k 0.8×	680 0.8×	852 1.0×	415 0.6×	338 0.8×	58	2.5k
May Alakl France	5	2.4k 0.9×	847 0.9×	722 0.9×	543 0.8×	354 0.9×	8	2.9k
Tsai‐Shen Yang Taiwan	11	2.8k 1.0×	1.3k 1.5×	1.1k 1.4×	579 0.8×	588 1.4×	19	3.7k
Linda Mol Netherlands	20	2.2k 0.8×	627 0.7×	920 1.1×	506 0.7×	555 1.4×	45	2.7k
D. Méry-Mignard France	16	2.7k 1.0×	1.1k 1.2×	979 1.2×	596 0.9×	383 0.9×	26	3.2k
Ralph Wong Canada	18	2.8k 1.0×	953 1.1×	1.2k 1.4×	513 0.7×	487 1.2×	36	3.4k
Jean-Luc Canon Belgium	15	2.3k 0.8×	486 0.5×	1.1k 1.3×	330 0.5×	522 1.3×	31	2.8k

Countries citing papers authored by Daniel Hendler

Since Specialization

Citations

This map shows the geographic impact of Daniel Hendler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Hendler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Hendler more than expected).

Fields of papers citing papers by Daniel Hendler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Hendler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Hendler. The network helps show where Daniel Hendler may publish in the future.

Co-authorship network of co-authors of Daniel Hendler

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Hendler. A scholar is included among the top collaborators of Daniel Hendler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Hendler. Daniel Hendler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Asher, Nethanel, et al.. (2025). Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation. Cancer Immunology Immunotherapy. 74(8). 260–260.

Doweck, Ilana, Aron Popovtzer, Daniel Hendler, et al.. (2023). First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma – A real-world experience from Israel. Frontiers in Oncology. 13. 1117804–1117804. 11 indexed citations

Gramont, Aimery de, Arié Figer, Michel Seymour, et al.. (2023). Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology. 41(33). 5080–5089. 10 indexed citations

Kuchuk, Iryna, Tzippy Shochat, Aarón Sulkes, et al.. (2021). Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. Breast Cancer Research and Treatment. 188(2). 379–387. 2 indexed citations

Babiker, Hani M., Erkut Borazanci, Vivek Subbiah, et al.. (2020). 1031P Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type I IFN signaling in solid tumours. Annals of Oncology. 31. S711–S712. 2 indexed citations

Sarfaty, Michal, Hadar Goldvaser, Daniel Hendler, et al.. (2020). Abstract P1-18-33: Taxane versus vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with metastatic HER2-positive breast cancer - A retrospective two-center study. Cancer Research. 80(4_Supplement). P1–18. 1 indexed citations

Yerushalmi, Rinat, Alexandra Benouaich‐Amiel, Daliah Tsoref, et al.. (2020). Central nervous system metastases in breast cancer: the impact of age on patterns of development and outcome. Breast Cancer Research and Treatment. 185(2). 423–432. 5 indexed citations

Stemmer, Salomon M., Aarón Sulkes, Victoria Neiman, et al.. (2019). Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer. Journal of Oncology. 2019. 1–7. 4 indexed citations

Goldvaser, Hadar, Shulamith Rizel, Daniel Hendler, et al.. (2017). The association between smoking and breast cancer characteristics and outcome. BMC Cancer. 17(1). 624–624. 24 indexed citations

10.

Goldvaser, Hadar, Shulamith Rizel, Daniel Hendler, et al.. (2017). Abstract P5-08-25: The association between smoking and breast cancer characteristics and outcome. Cancer Research. 77(4_Supplement). P5–8.

11.

Goldvaser, Hadar, Shulamit Rizel, Daniel Hendler, et al.. (2016). The Association between Angiotensin Receptor Blocker Usage and Breast Cancer Characteristics. Oncology. 91(4). 217–223. 4 indexed citations

12.

Sulkes, Aarón, Tzippy Shochat, Daliah Tsoref, et al.. (2016). Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations. Breast Cancer Research and Treatment. 157(3). 511–516. 29 indexed citations

13.

Ollech, Ayelet, Salomon M. Stemmer, Sharon Merims, et al.. (2016). Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato‐oncology clinic. International Journal of Dermatology. 55(4). 473–478. 6 indexed citations

14.

Goldvaser, Hadar, Shulamith Rizel, Daniel Hendler, et al.. (2016). The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics. International Journal of Endocrinology. 2016. 1–9. 5 indexed citations

15.

Yerushalmi, Rinat, Hadar Goldvaser, Aarón Sulkes, et al.. (2014). Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 &12 in Breast Cancer Patients: A Retrospective Analysis. PLoS ONE. 9(10). e107273–e107273. 7 indexed citations

16.

Zer, Alona, Shulamit Rizel, Rony Braunstein, et al.. (2012). Tailoring Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Historical Prospective Study. Chemotherapy. 58(2). 95–101. 1 indexed citations

17.

Hendler, Daniel, Shulamith Rizel, Rinat Yerushalmi, et al.. (2011). Different Schedules of Granulocyte Growth Factor Support for Patients With Breast Cancer Receiving Adjuvant Dose-Dense Chemotherapy. American Journal of Clinical Oncology. 34(6). 619–624. 17 indexed citations

18.

Hendler, Daniel & Salomon M. Stemmer. (2010). Uncommon Reason for High Fluorodeoxyglucose Positron Emission Tomography Uptake. Journal of Clinical Oncology. 28(32). e659–e660. 1 indexed citations

19.

Gramont, Aimery de, Arié Figer, Michel Seymour, et al.. (2000). Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology. 18(16). 2938–2947. 3040 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact